It's not good spotting. It was written into the initial deal...

It's not good spotting. It was written into the initial deal with Carlyle/Abingworth back in August 15th 2022. It's a repeat of that exact statement (on that particular date). So whilst Hell's Gates wants to bag S77, It actually isn't unknown news. The whole purpose of the initial deal was to see out funding for Phase 3 clinical trials and commercialisation (upon FDA approval - should it succeed) with no further dilution to existing holders.

I think what's more important is the fact that OPT have come out and stated that the P3 enrolment is currently at over 80%. That could mean that enrolments are at 80.1%. Still relatively slow going. But if anyone is thinking of getting into a speccie buy, don't wait for positive news on results of trials. Get in now, but just remember that the market does get bored very quickly. Get in, lock it away and don't look.